Does Medicare Cover Pancreatic Cancer Treatment? 2026 Guide

Yes - Medicare covers pancreatic cancer treatment. Surgery (including the Whipple procedure), chemotherapy, radiation therapy, targeted drugs, and diagnostic imaging are all covered under Parts A, B, and D depending on the setting. For the roughly 66,000 Americans diagnosed with pancreatic cancer each year - with a median diagnosis age of 71 - Medicare is typically the primary insurer, making coverage details critically important.

This guide explains exactly what Medicare pays for at each stage of pancreatic cancer care.

Who Gets Pancreatic Cancer and Why Medicare Matters

Pancreatic cancer (exocrine pancreatic ductal adenocarcinoma, or PDAC, accounts for about 90% of cases) is the fourth leading cause of cancer death in the United States. The median age at diagnosis is 71 years old, meaning the majority of patients are either already on Medicare or age in during treatment.

Risk factors include smoking, type 2 diabetes, chronic pancreatitis, obesity, and hereditary conditions including BRCA1/2 mutations. Family history of pancreatic cancer is an important risk factor that also makes genetic testing relevant for Medicare patients.

About 15-20% of patients have surgically resectable (removable) tumors at diagnosis, and those patients have significantly better 5-year survival rates (around 20-25% with modern adjuvant chemotherapy vs. around 12% overall). Getting to surgery quickly - and understanding which Medicare parts cover it - is a priority for eligible patients.

Part A: Inpatient Hospital Coverage for Surgery

Medicare Part A covers inpatient hospital stays for pancreatic cancer surgery. The Whipple procedure and other pancreatic operations are almost always performed as inpatient admissions due to their complexity and recovery requirements.

The Whipple Procedure (Pancreaticoduodenectomy)

The Whipple procedure - pancreaticoduodenectomy in surgical terminology - is the standard operation for cancers located in the head of the pancreas, which is where roughly 70% of pancreatic cancers occur. The surgery removes:

  • The head of the pancreas
  • The duodenum (first part of the small intestine)
  • The gallbladder and part of the bile duct
  • Sometimes the lower portion of the stomach (a “classic Whipple”) or the pylorus is preserved (“pylorus-preserving Whipple”)

Hospital stays after a Whipple procedure typically run 7-10 days. At experienced high-volume centers (defined as 20+ Whipple procedures per year), 90-day mortality is under 3% and long-term outcomes are significantly better than at lower-volume hospitals. Medicare does not restrict which facility you can use, but research strongly supports choosing a high-volume center for this operation.

Distal Pancreatectomy

For tumors in the body or tail of the pancreas, the operation is a distal pancreatectomy - removal of the left portion of the pancreas, almost always combined with removal of the spleen (splenectomy). Hospital stay is typically 4-7 days.

Total Pancreatectomy

Rarely performed, total pancreatectomy removes the entire pancreas. Used for certain rare tumor types (some intraductal papillary mucinous neoplasms, or IPMNs) or in selected recurrences. Results in insulin-dependent diabetes and exocrine insufficiency requiring pancreatic enzyme replacement therapy (PERT) for life - covered under Part D.

Palliative Surgical Procedures

For the 80-85% of patients whose disease is not surgically resectable, palliative procedures may be needed to relieve biliary or duodenal obstruction:

  • Biliary bypass (hepaticojejunostomy or choledochojejunostomy): Surgical rerouting to relieve jaundice when a stent fails or is not suitable
  • Gastrojejunostomy: Bypass of duodenal obstruction

These procedures, when performed as inpatient admissions, are covered under Part A.

2026 Part A costs for inpatient surgery:

Inpatient daysYour cost (2026)
Days 1-60$1,736 deductible (one-time per benefit period)
Days 61-90$434/day
Days 91-150$868/day (lifetime reserve days)
Beyond 150 days100% of costs

A typical Whipple procedure stay (7-10 days) falls within days 1-60, so the total Part A cost is the $1,736 deductible. Medigap Plan G covers this deductible entirely.

Part B: Outpatient Coverage

Medicare Part B covers the majority of pancreatic cancer care outside of inpatient surgery - including all chemotherapy infusions, radiation therapy, diagnostic imaging, and physician visits.

Chemotherapy Infusions (Part B)

Drugs administered intravenously at an outpatient infusion center are covered under Part B as “incident to” physician services. Part B covers 80% of the Medicare-approved amount after the annual deductible ($257 in 2026); you pay the remaining 20%. For high-cost cancer drugs given multiple times per month, this 20% can add up significantly without supplemental coverage.

Standard first-line regimens for pancreatic cancer:

  • FOLFIRINOX (fluorouracil + leucovorin + irinotecan + oxaliplatin): Given every two weeks as an infusion lasting 46-48 hours (the fluorouracil component is given as a continuous infusion via pump). Reserved for patients with good performance status (ECOG 0-1). All four agents are covered under Part B as infused drugs.
  • Gemcitabine + nab-paclitaxel (Abraxane): Given on days 1, 8, and 15 of a 28-day cycle. Both gemcitabine and nab-paclitaxel are IV agents covered under Part B. This is the preferred first-line regimen for many Medicare patients who cannot tolerate FOLFIRINOX intensity.
  • Gemcitabine alone: For frailer patients or those with reduced organ function. Weekly infusions for 3 of every 4 weeks.

Adjuvant (post-surgery) chemotherapy:

After a Whipple procedure or other resection, adjuvant chemotherapy significantly improves survival. The current standard is modified FOLFIRINOX (mFOLFIRINOX) for 6 months or gemcitabine + capecitabine. The IV components are covered under Part B; oral capecitabine is covered under Part D (see below).

Second-line and beyond:

FOLFOX (fluorouracil + oxaliplatin) or nanoliposomal irinotecan (Onivyde) + fluorouracil are common second-line options, all covered under Part B as infused agents.

Radiation Therapy (Part B)

External beam radiation therapy for pancreatic cancer is covered under Part B:

  • Stereotactic body radiation therapy (SBRT) / stereotactic ablative radiotherapy (SABR): 3-5 highly focused radiation treatments to the tumor with high precision. Preferred for pancreatic cancer because it delivers a high dose in few sessions while minimizing radiation to adjacent structures (duodenum, stomach, bowel).
  • Standard external beam radiation therapy (EBRT): Longer courses (typically 25-28 sessions over 5-6 weeks), sometimes given concurrently with chemotherapy (chemoradiation).
  • Intraoperative radiation therapy (IORT): Radiation delivered directly to the tumor bed during surgery at specialized centers. Covered under Part A/B when medically necessary.

Part B covers 80% of the Medicare-approved amount for each radiation session. For SBRT (5 sessions), the 20% coinsurance is paid on 5 visits; for EBRT (25-28 sessions), coinsurance is paid on each outpatient visit.

Diagnostic Imaging and Lab Tests (Part B)

Medicare covers all diagnostic tests ordered by an enrolled provider as medically necessary:

  • Multiphase CT scan of the abdomen and pelvis (pancreatic protocol CT with contrast): The primary imaging study for diagnosis, staging, and surgical planning
  • MRI/MRCP (magnetic resonance cholangiopancreatography): For evaluating ductal anatomy, biliary system, and liver lesions
  • Endoscopic ultrasound (EUS) with fine-needle biopsy: The preferred method for tissue diagnosis; a biopsy guided by ultrasound through an endoscope. Covered under Part B as an outpatient procedure.
  • PET scan: For staging evaluation and detecting distant metastases
  • CA 19-9 tumor marker blood test: Covered when ordered for diagnosis or monitoring treatment response
  • CEA and other tumor markers: Also covered when medically indicated

Biliary Procedures (Part B)

Biliary obstruction (jaundice) is a common complication of pancreatic head tumors. ERCP (endoscopic retrograde cholangiopancreatography) with stent placement is a Part B outpatient procedure covered when medically necessary. ERCP relieves the obstruction by placing a plastic or metal stent in the bile duct. If endoscopic access fails, percutaneous transhepatic cholangiography (PTC) with biliary drain placement is an alternative - also covered under Part B.

Genetic Testing (Part B)

Medicare covers germline (blood) genetic testing for BRCA1 and BRCA2 mutations when ordered by an enrolled provider for a patient with pancreatic cancer. This testing is clinically important because:

  1. BRCA2 mutations are found in approximately 5-7% of pancreatic cancer patients, and BRCA1 in about 1-2%
  2. BRCA-mutated tumors respond to PARP inhibitor therapy (olaparib - see Part D section)
  3. Positive results have implications for first-degree relatives

Somatic tumor genomic profiling (next-generation sequencing, or NGS) of the tumor is also covered when ordered to identify actionable alterations (KRAS, BRAF, NTRK, MSI-H, TMB, SMAD4). Medicare National Coverage Determination (NCD 90.2) covers FDA-approved companion diagnostics.

Physician and Specialist Visits (Part B)

All office visits, consultations, and follow-up appointments with:

  • Surgical oncologist / hepato-pancreato-biliary (HPB) surgeon
  • Medical oncologist
  • Radiation oncologist
  • Gastroenterologist
  • Palliative care specialist
  • Registered dietitian (critical after Whipple procedure for enzyme dosing and nutrition)

are covered at 80% after the Part B deductible. The annual deductible is $257 in 2026.

Part D: Oral Cancer Drugs

Medicare Part D prescription drug plans cover oral medications used in pancreatic cancer treatment.

Olaparib (Lynparza) for BRCA-Mutated Pancreatic Cancer

Olaparib is a PARP inhibitor approved by the FDA in 2019 as maintenance therapy for patients with germline BRCA1 or BRCA2 mutations whose pancreatic cancer has not progressed on first-line platinum-based chemotherapy. This is a targeted therapy that works specifically in BRCA-mutated tumors and represents one of the few targeted options available in pancreatic cancer.

Olaparib is taken as oral tablets twice daily and is covered under Part D as a specialty-tier drug. Without assistance, monthly costs can reach $8,000-$12,000. The 2025 $2,000 annual Part D out-of-pocket cap means your maximum personal cost in a calendar year is $2,000 (after which Medicare covers 60% and Part D plans cover the remainder, with no further cost-sharing). The Low Income Subsidy (Extra Help) program can reduce this to $4.50-$11.20 per month for qualifying enrollees.

Capecitabine (Xeloda)

Capecitabine is an oral fluoropyrimidine (similar to fluorouracil but taken as a pill) used in adjuvant chemotherapy combinations after surgery or as part of maintenance regimens. It is covered under Part D, typically on a preferred or non-preferred brand tier depending on the plan.

Erlotinib (Tarceva)

Erlotinib is an EGFR inhibitor that was historically combined with gemcitabine and showed a small survival benefit (about 2 weeks median) in a landmark trial. It is rarely used now due to limited efficacy compared to FOLFIRINOX and gemcitabine + nab-paclitaxel, but remains a covered Part D drug if prescribed.

Pancreatic Enzyme Replacement Therapy (PERT)

After a Whipple procedure or total pancreatectomy, the exocrine function of the pancreas is lost or impaired. Pancreatic enzyme replacement therapy (pancrelipase - Creon, Zenpep, Pancreaze) must be taken with every meal and snack for life. PERT is covered under Part D as a prescription drug. Without insurance, Creon can cost $600-$900 per month, making Part D coverage essential.

Insulin (Post-Surgical Diabetes)

After total pancreatectomy - and in some cases after Whipple procedure - patients develop insulin-dependent diabetes. Insulin and diabetes supplies (glucose meters, test strips, continuous glucose monitors) are covered under Part D. CGM devices may also be covered under Part B as DME.

2026 Cost Summary

TreatmentMedicare PartYour share (without Medigap)
Whipple procedure (hospital stay 7-10 days)Part A$1,736 deductible
Distal pancreatectomy (hospital stay 4-7 days)Part A$1,736 deductible
Chemotherapy infusion (each session)Part B20% coinsurance after $257/year deductible
FOLFIRINOX cycle (4 drugs per infusion)Part B20% of approved amount per drug
Radiation therapy (each outpatient session)Part B20% coinsurance
Oncologist office visitsPart B20% coinsurance
EUS with biopsyPart B20% coinsurance
CT scan / PET scanPart B20% coinsurance
Olaparib (Lynparza) - annual maximumPart D$2,000 (after $2,000 OOP cap)
CapecitabinePart DVaries by plan tier
Pancreatic enzymes (PERT)Part DStandard Part D cost-sharing

With Medigap Plan G: The $1,736 Part A deductible is covered. The 20% Part B coinsurance on all outpatient services is covered after you pay the Plan G annual deductible ($240 in 2026). This eliminates most out-of-pocket costs for surgery, chemotherapy, and radiation.

Without supplemental coverage: The 20% Part B coinsurance on a $6,000 monthly chemotherapy regimen would be $1,200 per month - $14,400 per year for chemotherapy alone, in addition to the Part A surgery deductible.

Medicare Advantage Considerations

If you have a Medicare Advantage plan (Part C), the same services are covered as under Original Medicare, but with important differences:

  • Prior authorization: Most Medicare Advantage plans require prior authorization for surgery, chemotherapy, and advanced imaging. Delays in authorization can delay cancer treatment. If your plan denies a claim, you have the right to appeal - and for cancer, this is worth pursuing aggressively.
  • Network restrictions: HMO-type plans require you to use in-network providers. For pancreatic cancer, where high-volume surgical centers (which may be academic medical centers or cancer centers) produce better outcomes, check that your preferred center is in-network before proceeding.
  • Drug coverage (Part D equivalent): Most Medicare Advantage plans include prescription drug coverage. Confirm that olaparib or capecitabine is on the plan’s formulary and at what cost tier.

If you are newly diagnosed and not yet on Medicare, review your plan choice carefully. If you are already enrolled in a Medicare Advantage plan, you can switch to Original Medicare + Medigap during certain special enrollment periods, though Medigap underwriting applies in most states for those over 65 who are past their initial enrollment period.

Medigap Plan G: Eliminating the 20% Coinsurance

For pancreatic cancer patients, Medigap Plan G is the most financially protective supplement. Here is what it covers on top of Original Medicare:

  • Part A deductible ($1,736): Covered in full - no cost for the inpatient surgery stay
  • Part B 20% coinsurance: Covered on all outpatient services (chemotherapy, radiation, imaging, physician visits) after the Plan G deductible ($240 in 2026)
  • Part A skilled nursing facility coinsurance: Covered for days 21-100 if you need post-surgical rehabilitation
  • Foreign travel emergency: Covered up to plan limits

With Plan G, the out-of-pocket maximum for all Part A and Part B services is essentially limited to $240 (the annual deductible). This is especially valuable for cancer patients receiving monthly chemotherapy infusions over many months.

Medicare Savings Programs: Help with Cost-Sharing

If you have limited income and assets, four Medicare Savings Programs (MSPs) are available through Medicaid:

  • Qualified Medicare Beneficiary (QMB): Pays Part A and B premiums, deductibles, and coinsurance. Providers enrolled in QMB cannot bill you for these costs.
  • Specified Low-Income Medicare Beneficiary (SLMB): Pays the Part B premium only
  • Qualifying Individual (QI): Pays part of the Part B premium
  • Qualified Disabled and Working Individuals (QDWI): For certain individuals under 65 with disabilities

Income limits for 2026: QMB starts at around $1,255/month (individual) or $1,703/month (married couple). Assets limits and exact figures vary by state. Apply through your state Medicaid office.

Extra Help (Low Income Subsidy): Separately, the Extra Help program for Part D reduces drug costs significantly - including for olaparib and other specialty cancer drugs.

5 Steps to Get the Best Coverage for Pancreatic Cancer

  1. Confirm your Medicare is active and your providers are enrolled. Call 1-800-MEDICARE or check medicare.gov to verify your enrollment in Parts A, B, and D (or your Advantage plan). Confirm your surgeon, oncologist, and treatment facility are enrolled Medicare providers.

  2. Ask your surgical team about volume. Request statistics on how many Whipple procedures or pancreatic resections the surgeon and hospital perform per year. High-volume centers (20+ Whipple procedures per year) have significantly lower complication and mortality rates. Medicare coverage is the same regardless of volume - you can choose any Medicare-enrolled facility.

  3. Request genetic testing early. Ask your oncologist to order germline BRCA1/2 testing and somatic tumor NGS profiling from the tumor biopsy. These tests are covered under Part B and determine whether you are eligible for olaparib or clinical trials. BRCA results are also important for your family members.

  4. Review your Part D formulary for olaparib and capecitabine. If you are BRCA-positive, olaparib is a likely maintenance therapy after chemotherapy. Confirm it is on your plan’s formulary before starting. Apply for the $2,000 annual out-of-pocket cap (Part D) to understand your maximum annual drug cost.

  5. Ask about palliative care from day one. Medicare covers palliative care consultations and services starting at diagnosis - you do not have to be in hospice to receive palliative care. Palliative care improves quality of life and helps manage pain, nausea, and nutrition challenges during treatment.

Frequently Asked Questions

Does Medicare cover the Whipple procedure?

Yes. The Whipple procedure (pancreaticoduodenectomy) is covered under Medicare Part A as an inpatient hospital surgery. Your cost is the Part A deductible ($1,736 in 2026) for a stay of up to 60 days. With Medigap Plan G, the deductible is covered and your personal cost is essentially zero for the hospitalization.

Does Medicare cover chemotherapy for pancreatic cancer?

Yes. All intravenous chemotherapy regimens for pancreatic cancer - including FOLFIRINOX and gemcitabine + nab-paclitaxel - are covered under Medicare Part B when administered at an outpatient infusion center. Medicare pays 80%; you pay 20% after the annual deductible.

Does Medicare cover olaparib (Lynparza) for pancreatic cancer?

Yes, if you have a BRCA1 or BRCA2 mutation. Olaparib (Lynparza) is covered under Medicare Part D for maintenance therapy in BRCA-mutated pancreatic cancer. Due to the $2,000 annual Part D out-of-pocket cap, your maximum personal cost for olaparib (or any Part D drug) is $2,000 per calendar year.

Does Medicare cover SBRT (stereotactic body radiation therapy) for pancreatic cancer?

Yes. SBRT and standard external beam radiation therapy for pancreatic cancer are covered under Part B as outpatient services. Medicare pays 80%; you pay 20% per session.

Does Medicare cover pancreatic enzyme replacement therapy (Creon) after Whipple surgery?

Yes. Pancreatic enzyme replacement therapy (PERT) - including Creon, Zenpep, and Pancreaze - is covered under Medicare Part D as a prescription drug. PERT is essential after any pancreatic surgery that removes or impairs exocrine function.

Does Medicare cover endoscopic ultrasound (EUS) for diagnosing pancreatic cancer?

Yes. Endoscopic ultrasound with fine-needle aspiration biopsy (EUS-FNA) is covered under Medicare Part B as an outpatient procedure when ordered by an enrolled provider as medically necessary for diagnosis.

What if my Medicare Advantage plan denies prior authorization for surgery or chemotherapy?

You have the right to appeal. For urgent cancer care, request an expedited appeal - Medicare Advantage plans must respond within 72 hours for urgent cases. If the internal appeal fails, you can request an independent external review. Contact your State Health Insurance Assistance Program (SHIP) for free help navigating appeals.

Does Medicare cover clinical trials for pancreatic cancer?

Yes. Medicare covers routine care costs during clinical trials that meet Medicare’s criteria. This includes chemotherapy, lab tests, imaging, and physician visits that you would receive as standard care regardless of trial participation. Clinical trials investigating novel treatments for pancreatic cancer are ongoing at major cancer centers and can be found at clinicaltrials.gov.

Sources

Fact-checked and reviewed by Alex Johnson, Editor. See our Editorial Policy for sourcing standards.